Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
Incyte Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for various cancers and inflammatory diseases. Their main products include treatments for myelofibrosis, lymphoma, biliary tract cancer, and graft-versus-host disease, with a pipeline of additional drugs in clinical development. Incyte operates globally, selling its products through various pharmacy and distribution channels.
AI-generated summary. Not investment advice.